SynthesisJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy and Safety of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma.Advances in radiation oncology · 2026Article
- Bocca's Technique Hemipharyngo-Total-Laryngectomy for Right Pyriform Sinus Squamous Cell Carcinoma.The Laryngoscope · 2026Article
- Comparison of induction chemotherapy followed by concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by surgery and (chemo)radiotherapy in locoregionally advanced hypopharyngeal carcinoma: a prospective cohort study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Transoral robotic surgery and neck dissection for hypopharyngeal cancer: long-term prognostic factors and survival outcomes.Journal of robotic surgery · 2026Article
- Pretreatment nodal SUVmax predicts neck progression in hypopharyngeal cancer undergoing definitive chemoradiotherapy, while higher radiotherapy dose improves regional control particularly in the high SUV-N subgroup: a long-term outcome study.American journal of cancer research · 2026Article
- Radiotherapy for Hypopharyngeal Carcinoma: Analysis of Multi-institutional Data From Over 170 Patients.Cureus · 2025Article
- Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Inflammation as a mediator between neck adipose tissue and tumor aggressiveness in hypopharyngeal and laryngeal squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Prognostic Factors and Long-Term Outcome Prediction in Patients with Hypopharyngeal Carcinoma Treated with (Chemo)radiotherapy: Development of a Prognostic Model.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceThe management of hypopharyngeal squamous cell carcinoma (HPSCC) continues to be one of the most formidable challenges in the realm of head and neck oncology.
objectivesThe aim of this meta-analysis was to evaluate the disparity in survival outcomes between upfront surgery and upfront concurrent chemoradiotherapy as the primary treatment modality in patients with HPSCC.
designSystemic review with meta-analysis.
settingThe meta-analysis was conducted in strict accordance with the PRISMA guideline. A literature search through PubMed, EMBASE, and the Cochrane Library were conducted until January 2023. The adjusted hazard ratio (aHR) with 95% confidence intervals (CIs) of different survival outcomes were extracted and pooled.
participantsStudies that incorporated HPSCC patients without receiving induction chemotherapy.
interventionsUpfront surgery versus upfront concurrent chemoradiotherapy.
main outcome measuresOverall survival (OS) and disease-free survival (DFS).
resultsEight studies published between 2015 and 2023, with a pooled patient population of 1619, were included in this meta-analysis. The outcomes reveal that upfront surgery was notably linked with improved OS (aHR 0.66, 95% CI 0.57-0.78) and DFS (aHR 0.75, 95% CI 0.63-0.90). Subgroup analyses were conducted to investigate the impact of the overall stage of the tumor and the extent of surgery on OS. In patients with advanced HPSCC (stages III and IV), upfront surgery remained associated with better OS (aHR 0.65, 95% CI 0.56-0.77). Concerning the extent of surgery, both subgroups exhibited a superior OS outcome associated with upfront surgery (exclusive total laryngopharyngectomy group: aHR 0.54, 95% CI 0.39-0.75; total/partial laryngopharyngectomy group: aHR 0.71, 95% CI 0.59-0.84). CONCLUSIONS AND RELEVANCE: The results demonstrated that upfront surgery showed better OS and DFS than concurrent chemoradiation and remind the clinicians of the potential reduction in survival outcomes when choosing concurrent chemoradiotherapy as primary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.